Skip to main content

RESPUESTA IMMUNE DURANTE EL REBOTE VIRAL DESPUES DE INTERRUMPIR EL CART Y SU RELACION CON LA RESPUESTA INMUNE DURANTE LA FASE AGUDA DE LA INFECCION POR VIH. NUEVOS METODOS DE MONITORIZACION DE LAS ATI

PI20/01039

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO INV GERMANS TRIAS I PUJOL
Execution centre FUNDACION IRSICAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection, a randomized, placebo-controlled phase 1 trial

  • Bailón, Lucía|||0000-0001-7277-9314
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Escribà, Tuixent|||0000-0001-9467-7802
  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Parera, Mariona|||0000-0002-0756-8307
  • Casadellà, Maria|||0000-0002-4115-2305
  • Lopez, Miriam
  • Pérez, Francisco
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Coll, Josep
  • Pérez, Félix|||0000-0002-6799-9272
  • Rivero, Ángel|||0000-0003-2136-0702
  • Leselbaum, Anne R.
  • McGowan, Ian
  • Sengupta, Devi
  • Wee, Edmund G.
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Paredes, Roger|||0000-0002-6553-691X
  • Alarcón-Soto, Yovaninna|||0000-0002-9977-8634
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Brander, Christian|||0000-0002-0548-5778
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Benet, Susana|||0000-0002-2219-8826
  • Cobarsi, Patricia|||0000-0003-3977-230X
  • Geleziunas, Romas
  • Loste, Cora
  • Meulbroek, Michael
  • Miranda, Cristina
  • Muñoz-Moreno, José Antonio|||0000-0002-7239-5422
  • Naval, Jordi
  • Nieto Gil-Ortega, Aroa|||0000-0001-8477-5062
  • Pujol Vila, Ferran|||0000-0002-6811-2426
  • Puig, Jordi|||0000-0002-4075-0346
HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV) vaccine immunogen designed to elicit cellular immune responses to HIV targets associated with viral control in humans. The AELIX-002 trial was a randomized, placebo-controlled trial to evaluate as a primary objective the safety of a combination of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines in 45 early-antiretroviral (ART)-treated individuals (44 men, 1 woman; NCT03204617). Secondary objectives included T-cell immunogenicity, the effect on viral rebound and the safety of an antiretroviral treatment interruption (ATI). Adverse events were mostly mild and transient. No related serious adverse events were observed. We show here that HTI vaccines were able to induce strong, polyfunctional and broad CD4 and CD8 T-cell responses. All participants experienced detectable viral rebound during ATI, and resumed ART when plasma HIV-1 viral load reached either.